OSE Immunotherapeutics Balance Sheet Health
Financial Health criteria checks 1/6
OSE Immunotherapeutics has a total shareholder equity of €23.0M and total debt of €41.9M, which brings its debt-to-equity ratio to 182.4%. Its total assets and total liabilities are €82.1M and €59.1M respectively.
Key information
182.4%
Debt to equity ratio
€41.91m
Debt
| Interest coverage ratio | n/a |
| Cash | €18.67m |
| Equity | €22.98m |
| Total liabilities | €59.08m |
| Total assets | €82.05m |
Recent financial health updates
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Recent updates
We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Oct 02We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt
Apr 30OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
May 11Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?
May 08Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher
Mar 16How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?
Dec 01Financial Position Analysis
Short Term Liabilities: OSE's short term assets (€30.5M) exceed its short term liabilities (€18.8M).
Long Term Liabilities: OSE's short term assets (€30.5M) do not cover its long term liabilities (€40.3M).
Debt to Equity History and Analysis
Debt Level: OSE's net debt to equity ratio (101.1%) is considered high.
Reducing Debt: OSE's debt to equity ratio has increased from 7.2% to 182.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OSE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.5% each year